Tumorigenicity and immunogenicity in a murine model of B-cell leukemia/lymphoma (BCL1)

S. Morecki*, A. Nagler, Z. Zakay-Rones, M. Schlesinger, A. Lubina-Salomon, T. Pugatsch, Y. Moshel, S. Slavin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Multiple injections of intact irradiated BCL1 cells, a murine B-cell leukemia/lymphoma can trigger a dose-dependent anti-tumor immune response in naive syngeneic mice. The ability to induce anti-BCL1 immunity and the effect of various cell-modifications on BCL1 tumorigenicity and immunogenicity was evaluated. Newcastle disease virus (NDV) infection or transfer of cytokine genes by both retroviral and Adeno 5 vectors affect neither tumorigenicity nor immunogenicity of BCL1 cells given as a non-immunogenic cell-dose. New ways will have to be developed to elicit a reliable and reproducible anti-tumor effect in spontaneously arising and non-immunogenic hematological malignancies.

Original languageEnglish
Pages (from-to)831-835
Number of pages5
JournalLeukemia Research
Issue number9
StatePublished - Sep 1998
Externally publishedYes


FundersFunder number
Israeli Cancer Association930120-B
Baxter Healthcare Corporation


    • Cytokine gene transfer
    • Immunogenicity
    • Tumorigenicity
    • Viral infection


    Dive into the research topics of 'Tumorigenicity and immunogenicity in a murine model of B-cell leukemia/lymphoma (BCL1)'. Together they form a unique fingerprint.

    Cite this